Teva EVP Granted 141,478 Restricted Share Units

Teva Pharmaceutical Industries executive Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical Officer, received 141,478 restricted share unitsJanuary 27, 2026.

Rhea-AI Filing Summary

Teva Pharmaceutical Industries executive Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical Officer, received 141,478 restricted share unitsJanuary 27, 2026. Each unit represents a right to receive one ordinary share or, at the committee’s option, the cash value of one share.

The restricted share units were earned after performance criteria were met and remain subject to time-based vesting, scheduled to vest on March 3, 2026. Following this award, Hughes directly beneficially owned 141,478 derivative securities tied to Teva ordinary shares.

Insider Trade Summary

Grant/Award: 141,478 shares

Grant/Award 1 txn

Insider Hughes Eric A

Role See "Remarks"

Type	Security	Shares	Price	Value
Grant/Award	Restricted Share Units	141,478	$0.00	$0.00

Holdings After Transaction: Restricted Share Units — 141,478 contracts (Direct)

Footnotes (3)

1. F1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
2. F2. Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 3, 2026.
3. F3. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the latest Form 4 for TEVA report for Eric A. Hughes?

The Form 4 reports that Eric A. Hughes received 141,478 restricted share units on January 27, 2026. These units relate to Teva ordinary shares and were granted after performance criteria were satisfied, with remaining vesting based on time until March 3, 2026.

How many Teva restricted share units did Eric A. Hughes receive?

Eric A. Hughes received 141,478 restricted share units in this transaction. The award was recorded at a price of $0 per unit, reflecting a grant rather than an open-market purchase, and brought his directly held derivative securities tied to Teva shares to 141,478 units.

When do Eric A. Hughes’s TEVA restricted share units vest?

The restricted share units granted to Eric A. Hughes will vest on March 3, 2026. They were awarded after performance criteria were met but remain subject to time-based vesting, meaning Hughes must remain eligible through that vesting date to receive the underlying value.

What does each TEVA restricted share unit granted to Eric A. Hughes represent?

Each restricted share unit represents a contingent right to receive one Teva ordinary share at settlement. Alternatively, at the Human Resources and Compensation Committee’s option, Hughes may receive the cash value of one ordinary share instead of the share itself upon settlement.

How many TEVA derivative securities does Eric A. Hughes own after the grant?

After the reported grant, Eric A. Hughes beneficially owns 141,478 derivative securities directly. These are restricted share units linked to Teva ordinary shares, awarded for meeting performance criteria and still subject to time-based vesting until March 3, 2026.

Are Eric A. Hughes’s TEVA restricted share units linked to American Depositary Shares?

The filing states that Teva’s ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share. Since each restricted share unit is tied to one ordinary share, the economic interest can correspond to one American Depositary Share as well.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/29/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hughes Eric A

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See "Remarks"

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	01/27/2026		A		141,478		(2)	(2)	Ordinary Shares(3)	141,478	$0	141,478	D

Explanation of Responses:

1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

2. Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 3, 2026.

3. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Remarks:

Executive Vice President, Global R&D and Chief Medical Officer

	/s/ Dov Bergwerk as attorney-in-fact for Eric A. Hughes	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.